GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Liabilities-to-Assets

UPB (Upstream Bio) Liabilities-to-Assets : 0.03 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Upstream Bio's Total Liabilities for the quarter that ended in Dec. 2024 was $11.87 Mil. Upstream Bio's Total Assets for the quarter that ended in Dec. 2024 was $481.72 Mil. Therefore, Upstream Bio's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.03.


Upstream Bio Liabilities-to-Assets Historical Data

The historical data trend for Upstream Bio's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Liabilities-to-Assets Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24
Liabilities-to-Assets
6.75 2.05 0.03

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Jun24 Sep24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial - 2.05 1.60 1.69 0.03

Competitive Comparison of Upstream Bio's Liabilities-to-Assets

For the Biotechnology subindustry, Upstream Bio's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Upstream Bio's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Liabilities-to-Assets falls into.


;
;

Upstream Bio Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Upstream Bio's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=11.867/481.719
=0.02

Upstream Bio's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=11.867/481.719
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Upstream Bio  (NAS:UPB) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Upstream Bio Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Upstream Bio Business Description

Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.